Unprecedented access to novel CRISPR nucleases
Inscripta is a gene editing technology company dedicated to creating the tools needed to revolutionize how we feed, fuel, and heal humanity. This includes developing a family of CRISPR enzymes (called MADzymes), bespoke nucleases for researchers and commercial partners, and a full suite of gene editing tools (software, instruments, and reagents) that will significantly increase the speed and efficiency of precision gene editing.
Inscripta to Present First Data From Its Digital Genome Engineering Technology at Upcoming Synthetic Biology Conference
Results from a 200,000-edit library of an E. coli biosynthesis pathway show unprecedented scale and variety of edit types